Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US11028177B2 · kind B2 · utility
1Cited by
49References
47Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 6, 2017 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Feb 15, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.